Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

Circulation

Volumn 122, Issue 8, 2010, Pages 844-846

  Riddle, Matthew C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Mortality

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CARDIOVASCULAR RISK; GLYCEMIC CONTROL; HUMAN; HYPOTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 77956640139     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.960138     Document Type: Article

References (11)

1. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P, for the ACCORD Study Group. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol. 2007; 99(suppl 12A):34i-43i
2. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-2559.
3. Calles-Escandon J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33:721-727.
4. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S, for the ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated hemoglobin concentration on the risk of severe hypoglycaemia: post hoc epide-miological analysis of the ACCORD study. BMJ. 2010;340:b5444.
5. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Sperl-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiologic analysis of the ACCORD study. BMJ. 2010;430:b4909.
6. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff, DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER, for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. Diabetes Care. 2010;33:983-990.
7. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26:1485-1489.
8. Davis TME, Brown SGA, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Freemantle Study. J Clin Endocrinol Metab. 2010;95:2240-2247.
9. Leese GP, Wang J, Broomhill J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176-1180.
10. Puente EC, Silverstein J, Bree AJ, Musikantow DR, Wozniak DF, Maloney S, Daphna-Iken D, Fisher SJ. Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia. Diabetes. 2010;59:1055-1062.
11. Siegel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724-733.